This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Guilford Pharmaceuticals, Inc.. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: **Amy D Xing: Innovator in Pharmaceutical Compounds**
Introduction
Amy D Xing, an accomplished inventor based in Ellicott City, Maryland, has made significant contributions to the field of pharmaceuticals through her innovative research and patents. Her work focuses on the development of novel compounds that have therapeutic applications, particularly in inhibiting certain enzymes linked to various diseases.
Latest Patents
Amy holds one notable patent titled "Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use." This invention details symmetrically disubstituted aromatic compounds that modulate the activity of poly(ADP-ribose) glycohydrolase (PARG). Furthermore, it covers the therapeutic and prophylactic applications of these compounds, offering methods to treat diseases and disorders through the administration of effective doses.
Career Highlights
In her professional journey, Amy has been associated with Guilford Pharmaceuticals, Inc., where she continues to push the boundaries of pharmaceutical research. Her patented work emphasizes her ability to create solutions that target complex biological mechanisms, reflecting her expertise in the field.
Collaborations
Throughout her career, Amy has collaborated with several distinguished colleagues, including Jia-He Li and Dana Victor Ferraris. These collaborations highlight her ability to work alongside other skilled professionals, further advancing innovative solutions in the pharmaceutical industry.
Conclusion
With her inventive spirit and dedication to research, Amy D Xing exemplifies the impactful role of innovators in the pharmaceutical sector. Her contributions not only enhance medical science but also pave the way for future advancements in treating complex health issues.